115 related articles for article (PubMed ID: 4038476)
41. Inhibition of the classical and alternative pathways of human and guinea pig complement by pyran copolymer.
Webster GF; McArthur WP
Int Arch Allergy Appl Immunol; 1981; 66(3):304-9. PubMed ID: 6913544
[TBL] [Abstract][Full Text] [Related]
42. Polyglycolic acid-induced inflammation: role of hydrolysis and resulting complement activation.
Ceonzo K; Gaynor A; Shaffer L; Kojima K; Vacanti CA; Stahl GL
Tissue Eng; 2006 Feb; 12(2):301-8. PubMed ID: 16548688
[TBL] [Abstract][Full Text] [Related]
43. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
Ziccardi RJ
J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
[TBL] [Abstract][Full Text] [Related]
44. A simple hemolytic assay for bovine complement component C3.
Mhatre A; Aston WP
Vet Immunol Immunopathol; 1987 Jun; 15(3):239-51. PubMed ID: 3307130
[TBL] [Abstract][Full Text] [Related]
45. Fixation of C3 to platelets in vitro by antiplatelet antibody from patients with immune thrombocytopenic purpura.
McMillan R; Martin M
Br J Haematol; 1981 Feb; 47(2):251-6. PubMed ID: 7193475
[TBL] [Abstract][Full Text] [Related]
46. IgG on mouse erythrocytes augments activation of the human alternative complement pathway by enhancing deposition of C3b.
Moore FD; Fearon DT; Austen KF
J Immunol; 1981 May; 126(5):1805-9. PubMed ID: 6908606
[No Abstract] [Full Text] [Related]
47. IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model.
Wagner E; Platt JL; Howell DN; Marsh HC; Frank MM
J Immunol; 1999 Sep; 163(6):3549-58. PubMed ID: 10477630
[TBL] [Abstract][Full Text] [Related]
48. Isolation of rat IgM to IgG hybridoma isotype switch variants and analysis of the efficiency of rat Ig in complement activation.
Pluschke G; Bordmann G; Daoudaki ME; Lambris JD; Achtman M; Neibert M
Eur J Immunol; 1989 Jan; 19(1):131-5. PubMed ID: 2646134
[TBL] [Abstract][Full Text] [Related]
49. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
[TBL] [Abstract][Full Text] [Related]
50. The ability to sensitize host cells for destruction by autologous complement is a general property of lipoteichoic acid.
Weinreb BD; Shockman GD; Beachey EH; Swift AJ; Winkelstein JA
Infect Immun; 1986 Nov; 54(2):494-9. PubMed ID: 3533782
[TBL] [Abstract][Full Text] [Related]
51. Quantitative influence of antibody and complement coating of red cells on monocyte-mediated cell lysis.
Kurlander RJ; Rosse WF; Logue GL
J Clin Invest; 1978 May; 61(5):1309-19. PubMed ID: 96137
[TBL] [Abstract][Full Text] [Related]
52. Mixed IgA-IgG aggregates as a model of immune complexes in IgA nephropathy.
Waldo FB; Cochran AM
J Immunol; 1989 Jun; 142(11):3841-6. PubMed ID: 2715639
[TBL] [Abstract][Full Text] [Related]
53. C3 binds covalently to the C gamma 3 domain of IgG immune aggregates during complement activation by the alternative pathway.
Antón LC; Alcolea JM; Sánchez-Corral P; Marqués G; Sánchez A; Vivanco F
Biochem J; 1989 Feb; 257(3):831-8. PubMed ID: 2784671
[TBL] [Abstract][Full Text] [Related]
54. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro.
Mollnes TE; Andreassen IH; Høgåsen K; Hack CE; Harboe M
Mol Immunol; 1997 Jul; 34(10):719-29. PubMed ID: 9430199
[TBL] [Abstract][Full Text] [Related]
55. Binding of soluble immune complexes to human lymphoblastoid cells. I. Characterization of receptors for IgG Fc and complement and description of the binding mechanism.
Theofilopoulos AN; Dixon FJ; Bokisch VA
J Exp Med; 1974 Oct; 140(4):877-94. PubMed ID: 4139225
[TBL] [Abstract][Full Text] [Related]
56. Hematin promotes complement alternative pathway-mediated deposition of C3 activation fragments on human erythrocytes: potential implications for the pathogenesis of anemia in malaria.
Pawluczkowycz AW; Lindorfer MA; Waitumbi JN; Taylor RP
J Immunol; 2007 Oct; 179(8):5543-52. PubMed ID: 17911641
[TBL] [Abstract][Full Text] [Related]
57. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome.
Arvidsson I; Ståhl AL; Hedström MM; Kristoffersson AC; Rylander C; Westman JS; Storry JR; Olsson ML; Karpman D
J Immunol; 2015 Mar; 194(5):2309-18. PubMed ID: 25637016
[TBL] [Abstract][Full Text] [Related]
58. The failure to show a necessary role for C3 in the in vitro antibody response.
Waldmann H; Lachmann PJ
Eur J Immunol; 1975 Mar; 5(3):185-93. PubMed ID: 1086224
[TBL] [Abstract][Full Text] [Related]
59. Human serum induced opsonization of immunoglobulin G-coated polystyrene microspheres with complement components C3 and C4 as measured by flow cytometry.
Spycher MO; Spycher-Burger M; Späth PJ; Burckhardt JJ
J Immunol Methods; 1991 Dec; 145(1-2):83-92. PubMed ID: 1765669
[TBL] [Abstract][Full Text] [Related]
60. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.
Parker CJ; Wiedmer T; Sims PJ; Rosse WF
J Clin Invest; 1985 Jun; 75(6):2074-84. PubMed ID: 4008653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
